Bio Products Laboratory (BPL) announces today the completion of a US$370 million (£265 million) transaction for the sale of 25 of its 51 US-based plasma centres to Biomat USA Inc, a subsidiary of Grifols S.A., a global healthcare company. Approximately 730 employees will be transferring to Biomat as part of the deal.
The remaining 26 plasma centres will continue under BPL Plasma’s ownership and will focus on supplying plasma to BPL’s Therapeutics business based in the UK. This transaction secures BPL’s long-term supply of plasma for the plasma-derived medicines it produces and supplies to patients worldwide. BPL Plasma will continue to be a leader in the collection and supply of specialty plasma to BPL as well as third party customers.
BPL has made significant investments in recent years to grow the reach of its Therapeutics business, increasing production at its UK manufacturing base in Elstree, strengthening its commercial presence worldwide, investing in its R&D programmes and reliably delivering world class medicines for patients in areas including immunology, haemophilia, treatment of coagulation disorders and critical care.
Through strong team work and dedication, the BPL Therapeutics business has delivered double digit growth over the last two years, with sales in 2020 growing by +22% in the midst of the global pandemic.
On behalf of the BPL Board I would like to thank the whole BPL Plasma team for their efforts in leading the business through the pandemic and in completing this transaction. This deal reinforces BPL’s position as an integrated supplier of reliable, high-quality plasma-derived products to patients and healthcare professionals around the world.
David Gao
CEO and Vice Chairman of BPL
We could not be prouder of the accomplishments of our BPL Plasma business, growing its centre footprint by 50% since 2016 and making it a leader in plasma collections. The tenacity of our team throughout the COVID-19 pandemic is a testament to their professionalism and dedication. I want to thank them all for their efforts, including those colleagues that are today joining Grifols.
Marvin Dyke
President of BPL Plasma
US media enquiries:
Margaret Aitken, Aitken Communication
+1-302-419-4334
UK & Rest of the World media enquiries:
Sofia Newitt, Vico Partners
+44-(0)20 3957 5045
About Bio Products Laboratory (BPL)
Recognising the importance of plasma and with many years of experience in the industry, BPL supplies high-quality plasma derived medicines to meet the needs of clinicians, patients and customers globally. Headquartered in the United Kingdom and with plasma collection centres across the United States, we are dedicated to producing medicines for the treatment of immune deficiencies, bleeding disorders and infectious diseases as well for critical care. BPL invests in the latest R&D, technology and manufacturing methods, and continuously adapts to ensure that we continue to serve all our stakeholders effectively. For more information visit http://www.bplgroup.com
BPL consists of two operating divisions – BPL Plasma and BPL Therapeutics. BPL Plasma, headquartered in Austin, Texas and operating in the USA, collects plasma from donors, in around 26 centres across the US. BPL Plasma employs over 900 staff, to support the needs of donors and to ensure high-quality plasma collection in all their centres. Plasma collection is regulated by both FDA and MHRA, and BPL Plasma follow industry guidelines. BPL Plasma operates clean and safe plasma facilities, staffed with trained personnel, dedicated to supporting donors through the process that leads to the donation of plasma. Plasma is shipped to the headquarters of BPL Therapeutics in Elstree, United Kingdom. The plasma is fractionated, purified, and filled through the efforts of our over 1,000 employees involved in production, quality, R&D, commercial, customer services and administrative activities. BPL’s plasma derived medicines are commercially available in the UK, USA and 30 plus other countries around the world through our network of local affiliates and distribution partners.